The funding announced Monday by the Commerce Department is part of a total investment in the cluster that, with private money, is expected to exceed $40 billion. Photo via Getty Images

The Biden administration has reached an agreement to provide up to $6.4 billion in direct funding for Samsung Electronics to develop a computer chip manufacturing and research cluster in Texas.

The funding announced Monday by the Commerce Department is part of a total investment in the cluster that, with private money, is expected to exceed $40 billion. The government support comes from the CHIPS and Science Act, which President Joe Biden signed into law in 2022 with the goal of reviving the production of advanced computer chips domestically.

“The proposed project will propel Texas into a state of the art semiconductor ecosystem,” Commerce Secretary Gina Raimondo said on a call with reporters. “It puts us on track to hit our goal of producing 20% of the world’s leading edge chips in the United States by the end of the decade.”

Raimondo said she expects the project will create at least 17,000 construction jobs and more than 4,500 manufacturing jobs.

Samsung's cluster in Taylor, Texas, would include two factories that would make four- and two-nanometer chips. Also, there would be a factory dedicated to research and development, as well as a facility for the packaging that surrounds chip components.

The first factory is expected to be operational in 2026, with the second being operational in 2027, according to the government.

The funding also would expand an existing Samsung facility in Austin, Texas.

Lael Brainard, director of the White House National Economic Council, said Samsung will be able to manufacture chips in Austin directly for the Defense Department as a result. Access to advanced technology has become a major national security concern amid competition between the U.S. and China.

In addition to the $6.4 billion, Samsung has indicated it also will claim an investment tax credit from the U.S. Treasury Department.

The government has previously announced terms to support other chipmakers including Intel and Taiwan Semiconductor Manufacturing Co. in projects spread across the country.

A new ranking looks at the Houston companies with the most patents granted in 2022. Photo via Getty Images

These are the Houston companies with the most patents granted last year

by the numbers

Two major players in Houston’s energy industry are also major players in the patent arena.

A new ranking from the analytics arm of patent law firm Harrity & Harrity puts Saudi Aramco, whose North American headquarters is in Houston, and Halliburton, whose global headquarters is in Houston, puts them in a tie for the number of U.S. patents with 963 patents received in 2022. Saudi Aramco and Halliburton now share the title of Houston’s patent king.

Saudi Aramco saw a 12 percent rise in patents granted in 2022 compared with 2021, according to Harrity & Harrity’s Patent 300 report, while Halliburton experienced a 5 percent jump. Each company tied for 44th place among the top 300 U.S. patient recipients in 2022.

According to the report, Samsung Electronics (8,513 patents) knocked IBM off its longtime pedestal as the No. 1 recipient of U.S. patents. IBM (4,743 patents) now holds the No. 2 position.

Many of Aramco’s U.S. patents come from its R&D centers in Houston, Boston, and Detroit. The Houston R&D hub opened in 2014 and underwent an expansion three years later.

Aramco, a Saudi Arabia-based supplier of oil and natural gas, also generates patents through academic partnerships, such as the one it established last year with Rice University’s Carbon Hub. Aramco has committed $10 million over five years to the carbon initiative.

“While patents are a leading indicator of innovation, the ultimate goal is to create value through the development of solutions that help to address a particular need,” Aramco says. “Such results are often only possible with significant upfront investments, and patents make it possible to recoup these costs and potentially generate additional revenue through commercialization.”

Last year, Aramco boasted that it ranked first in the oil and gas industry for U.S. patents (864) granted in 2021. Until 2011, Aramco had received only 100 U.S. patents over a 78-year span.

“Many of the patents are for innovations Aramco uses itself for competitive advantage, although they can also be licensed to others, creating extra value for the company,” Jamil Bagawi, then the company’s chief engineer, wrote in 2021.

Halliburton also has ramped up its patenting efforts in recent years.

According to Houston law firm Yetter Coleman, those efforts kicked into high gear after Halliburton lost a fracking patent lawsuit to Tomball-based BJ Services, which is now out of business. In 2003, a Houston jury awarded $98 million in damages to BJ in the case, and Halliburton had to stop selling the system that allegedly infringed on BJ’s patent.

In the five years before the verdict, Halliburton averaged 142 patent awards a year, according to Yetter Coleman. The law firm reported in 2013 that Halliburton subsequently averaged 234 patents a year.

Today, of course, Halliburton has far exceeded those numbers. And it vigorously defends its growing patent portfolio. In September 2022, for instance, three subsidiaries of the oilfield services giant filed two lawsuits against Houston-based rival U.S. Well Services alleging infringement of 14 Halliburton patents.

IAM, a website that reports about the intellectual property industry, noted that when Halliburton sued U.S. Well Services, “IP professionals in the oil and gas industry may well have reached for the popcorn. Battles of this magnitude rarely break out in their slice of the patent world.”

Halliburton and Aramco may be the goliaths in Houston’s patent world, but they’re not the only local organizations to appear on the Patent 300 list for 2022. Other Houston-area companies that made the cut are:

  • Spring-based Hewlett Packard Enterprise, No. 84. The tech company received 511 U.S. patents in 2022, down 4 percent from the previous year.
  • Houston-based SLB (Schlumberger), No. 117. The oilfield services company received 372 U.S. patents in 2022, down 14 percent from the previous year.
  • Houston-based Baker Hughes, No. 123. The oilfield services company received 350 U.S. patents in 2022, down 11 percent from the previous year.
  • ExxonMobil, No. 156. The oil and gas company received 281 U.S. patents in 2022, down 8 percent from the previous year. It is in the process of moving its headquarters from Irving to Spring.
  • United Imaging Healthcare, No. 253. The Chinese healthcare equipment company, whose North American headquarters is in Houston, received 175 U.S. patents in 2022, up 31 percent from the previous year.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”